TACTI-004 will evaluate Immutep’s eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA ...
(RTTNews) - Immutep Limited (IMMP), on Tuesday announced that it has received regulatory support for its pivotal TACTI-004 Phase III trial evaluating eftilagimod alfa or efti in combination with ...
The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback